Teruki Honma

Practical synthesis of indolopyrrolocarbazoles

Abstract A practical method for the synthesis of an indolo[2,3-a]pyrrolo[3,4-c]carbazole ring system is described. The method involves two key processes: a coupling reaction between indole and substituted methylmaleimide portions using lithium hexamethyldisilazide (LiHMDS) as a base, and the oxidative cyclization of bisindolylmaleimide with palladium (II) chloride. We applied this method to the synthesis of arcyriaflavin B ( 5 ), C ( 6 ) and D (7).

Synthesis of Dissymmetric Indolocarbazole Glycosides Using the Mitsunobu Reaction at the Glycosylation Step

Abstract A novel method for the synthesis of N-glycosylated dissymmetric indolo[2,3-a]pyrrolo-[3,4-c]carbazole derivatives was developed by applying the Mitsunobu reaction to the N-glycosylation reaction of substituted indole substrates.

Synthesis and biological activities of NB-506 analogues modified at the glucose group.

A new indolocarbazole compound, NB-506 (1), modified at the glucose group yielded a beta-D-glucopyranoside, J-107,088 (2), which showed potent anticancer activity. A beta-D-ribofuranoside, J-109,534 (3), was found to be 6 times more potent than J-107,088 at inhibiting topoisomerase I.

Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.

In the course of a study of 6-N-amino-substituted analogues of NB-506 (1), a more potent anticancer drug, J-109,404 (2), in which the formyl group of NB-506 was replaced with a 1,3-dihydroxypropane group, was reported. A study of further modification in the positions of two hydroxyl groups at the indole rings of 2 resulted in the discovery of a 2,10-dihydroxy analogue, J-107,088 (3), which is a promising anticancer agent with a broader therapeutic window than J-109,404.